Beckman Coulter Genomics and Genpathway have announced a strategic partnership to offer customers whole-genome chromatin immunoprecipitation sequencing (ChIP-Seq) services.
The alliance is said to provide researchers investigating gene regulation and genetic pathways a single, inclusive source for services supporting genome-wide studies of transcription factor binding, gene transcription and epigenetic events.
ChIP-Seq is said to combine the sophistication of chromatin immunoprecipitation with the power of ultra-high-throughput next-generation DNA sequencing to enable the study of complex interactions between proteins and nucleic acids.
Mapping protein-DNA complexes in vivo on a genome-wide scale with ChIP-Seq builds a picture of the intricate network of interactions that regulate genes and genetic pathways in a sample.
Comparing ChIP-Seq results from different conditions - diseased versus normal cells, for example - can reveal distinguishing patterns of genetic regulation that may be biologically significant.
Beckman Coulter Genomics services include Sanger and next-generation DNA sequencing, gene expression profiling, genotyping and biologics testing.
The collaboration with Genpathway further expands the company's DNA sequencing applications portfolio, which is available to clients worldwide.
The start-to-finish ChIP-Seq services will include ChIP experimental design and consultation, antibody qualification, performance of ChIP assays with post-ChIP QC, next-generation sequencing and comprehensive data analysis.
